HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antithrombotic Therapy Improves ICU Mortality of Septic Patients with Peripheral Vascular Disease.

AbstractObjective:
The effectiveness of antithrombotic drugs for treating sepsis is controversial. Here, we explore the association between antithrombotic therapy and intensive care unit (ICU) mortality for septic patients with peripheral vascular disease.
Methods:
This retrospective cohort study uses data from the Medical Information Mart for Intensive Care (MIMIC)-III database. Kaplan-Meier survival analyses were used to examine mortality among different groups. Cox regression and marginal structural Cox models (MSCMs) were used to adjust for confounding factors. Main Results. The final cohort from the MIMIC-III database included 776 patients, of which 701 survived and 75 perished. The anticoagulant (AC) group and the antiplatelet-anticoagulation (AC-AP) group survived better than the group without antithrombotic treatment (non-AT). The AC and AC-AP groups showed a 0.363-fold and 0.373-fold risk of ICU mortality, respectively, compared with the non-AT group when controlling for age, gender, CRRT, alcohol, heart failure, hypertension, diabetes, obesity, renal failure, liver disease, INR, PT, PPT, and SpO2. Antiplatelet therapy did not reduce ICU mortality. The same trends were apparent from the MSCM. In addition, the AC-AP group exhibited a lower risk of bleeding complications.
Conclusion:
Although the antithrombotic group (AC and AC-AP groups) demonstrated a higher sequential organ failure assessment (SOFA) score than the group without antithrombotic treatment (non-AT group), the risk of ICU mortality was lower without increasing the risk of bleeding complications. Our study further suggested that anticoagulation therapy may benefit the prognosis of septic patients with peripheral vascular disease.
AuthorsShiqi Yuan, Chong Chen, Fengshuo Xu, Didi Han, Rui Yang, Shuai Zheng, Mengmeng Qiao, Xiaxuan Huang, Jun Lyu
JournalInternational journal of clinical practice (Int J Clin Pract) Vol. 2022 Pg. 1288535 ( 2022) ISSN: 1742-1241 [Electronic] India
PMID35685503 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Shiqi Yuan et al.
Chemical References
  • Anticoagulants
  • Fibrinolytic Agents
Topics
  • Anticoagulants (adverse effects)
  • Fibrinolytic Agents (therapeutic use)
  • Humans
  • Intensive Care Units
  • Peripheral Vascular Diseases
  • Prognosis
  • Retrospective Studies
  • Sepsis (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: